Dr. Guldner’s research delves deeply into the complex interplay of proteostasis within neurons—a critical cellular system responsible for protein synthesis, folding, recycling, and degradation. Maintaining proteostasis is essential for neuronal longevity, particularly given the decades-long lifespan of these cells. Alterations in these pathways lead to protein aggregation and cellular dysfunction, hallmarks observed in age-associated neurodegenerative disorders like Alzheimer’s disease. His laboratory aims to elucidate how disruptions in these finely tuned proteostatic mechanisms contribute to the early phases of brain aging, with the ultimate goal of targeting these processes to prevent or mitigate cognitive decline.

Another central pillar of Guldner’s work focuses on neuroimmune interactions within the brain’s microenvironment. The brain’s immune system is largely governed by microglia, resident macrophage-like cells that perform surveillance and response functions. By exploring how microglia detect and respond to neuronal stress signals—especially those elicited by aging—Dr. Guldner’s research sheds light on the immunological crosstalk that shapes brain health. His recent discoveries highlight the accumulation of neuron-derived synaptic proteins within microglia as a potential early biomarker of synaptic dysfunction and impending neurodegeneration, offering a novel perspective on the molecular exchanges that underpin brain aging.

Earlier in 2026, Dr. Guldner published a pivotal first-author paper in Nature, which demonstrated that aging facilitates the translocation of specific synaptic proteins from neurons into microglial cells. This protein transfer not only exemplifies a previously underappreciated route of molecular communication but also implicates the immune surveillance system as both a responder and potential mediator in neurodegenerative disease progression. This insight adds a new layer of complexity to the understanding of proteomic shifts within the aging brain’s microenvironment, suggesting new molecular targets for intervention.

Dr. Guldner’s interdisciplinary expertise extends beyond neurodegeneration. His work has also rigorously examined immune modulation mechanisms in cancer brain metastases, bringing a unique translational perspective to his studies of brain immune dynamics. This cross-disease approach equips him with a broader understanding of the immune system’s dualistic roles in maintaining brain homeostasis and contributing to pathology across different disease paradigms, thereby enabling innovative strategies that may apply to multiple neurological conditions.

The appointment of Dr. Guldner was facilitated through the generosity of the Ray and Dagmar Dolby Family Fund, spearheaded by David Dolby, CEO of Dolby Family Ventures. This philanthropic support is instrumental in recruiting pioneering scientists who can push the boundaries of foundational biomedical research. According to Salk Institute President Dr. Gerald Joyce, this strategic investment underscores the institute’s commitment to tackling early biological questions that form the basis for medical breakthroughs, especially in understanding how complex cellular processes evolve with age and yield disease.

In his own words, Dr. Guldner is energized by the collaborative scientific culture at Salk, where fundamental questions about life and aging are pursued with rigor and creativity. He emphasizes the importance of integrating multidisciplinary expertise to decode the cellular machinery of brain aging, an approach he believes will pave the way for new preventive and therapeutic modalities against Alzheimer’s and related disorders. His new laboratory will prioritize the development and application of sophisticated tools designed to monitor protein dynamics and cell-to-cell signaling in vivo, delivering unprecedented insights into the molecular substrates of brain aging.

The developmental trajectory that led to Dr. Guldner’s groundbreaking work includes a Bachelor of Science in biology from Moravian College, a doctoral degree from the University of Notre Dame, and postdoctoral training at Stanford University. His accomplishments have been recognized by the National Institute on Aging with the prestigious K99/R00 Pathway to Independence Award, signaling his potential to become a leading figure in neurobiology. This award supports his transition to independent research, underpinning his efforts to innovate in the study of aging and neuroimmune interactions.

As the Salk Institute continues to deepen its focus on neurodegeneration and brain aging, Dr. Guldner’s research is expected to stimulate cross-disciplinary initiatives encompassing immunobiology, cancer research, and molecular gerontology. His work exemplifies a modern neuroscience approach that combines cellular biology with systems-level understanding. Through novel molecular imaging and proteomic techniques, his studies will map the dynamic exchanges shaping the aging brain’s environment, offering vital clues into the earliest cellular events that foreshadow cognitive impairment.

David Dolby highlighted the pressing need for early-stage research and new technologies that allow scientists to visualize and interpret biological changes with heightened precision. The donation from the Dolby Family Fund, which enabled Dr. Guldner’s recruitment, is emblematic of this vision—empowering foundational discovery that promises to translate into clinical advances. Dolby expressed optimism that supporting investigators like Dr. Guldner will accelerate progress in developing innovative therapies for Alzheimer’s disease and other dementias that currently lack effective treatments.

Dr. Guldner’s vision integrates fundamental mechanistic exploration with translational aspirations, aiming to construct a detailed molecular and cellular framework of brain aging. By decoding how proteins and immune cells interact in the aging brain, his research endeavors to identify molecular choke points amenable to therapeutic targeting. Such interventions could transform how neurodegenerative diseases are diagnosed and managed, emphasizing prevention grounded in a deep understanding of brain cellular biology.

As he prepares to establish his laboratory at Salk, Dr. Guldner plans to foster collaborations that cut across traditional disciplinary boundaries. His work will leverage cutting-edge proteostasis assays, advanced neuroimmune imaging, and single-cell molecular profiling to expand the frontiers of brain aging research. Through integrated experimental approaches, his team will illuminate the mechanisms orchestrating neuronal proteome maintenance and microglial function across lifespan, setting the stage for innovative research into cognitive resilience.

The recruitment of Dr. Ian Guldner signals a promising era for the Salk Institute’s quest to decipher the biology of aging and neurodegeneration. His expertise and pioneering research align with the institute’s ethos of seeking fundamental biological truths as a foundation for transformative medical breakthroughs. As brain aging is a universal process with increasing societal impact, initiatives like Dr. Guldner’s are critical to fulfilling the urgent need for novel interventions that sustain cognitive health and quality of life into advanced age.

Subject of Research: Brain Aging, Alzheimer’s Disease, Cellular Communication Mechanisms, Proteostasis, Neuroimmune Interactions
Article Title: Not provided in the original content
News Publication Date: May 7, 2026
Web References: https://www.nature.com/articles/s41586-025-09987-9
Image Credits: Luci Valentine Photography
Keywords: Brain aging, Alzheimer’s disease, proteostasis, microglia, neurodegeneration, cellular communication, immune surveillance, protein dynamics, neuroimmune interactions, cognitive health, neurobiology, Salk Institute

Alpha-synuclein accumulation in neuronal cells is widely recognized as a central pathological feature in synucleinopathies. Despite extensive research, the molecular mechanisms that modulate α-synuclein aggregation remain only partially understood. Maddila and colleagues have identified that the methylation status of PP2A, a critical serine/threonine phosphatase involved in many cellular signaling pathways, plays a key regulatory role in the formation and clearance of α-synuclein aggregates.

PP2A is known for its broad involvement in cellular homeostasis, including the regulation of tau phosphorylation, cell cycle progression, and apoptosis. The study reveals that methylation of the catalytic subunit of PP2A significantly alters its activity and substrate specificity, thereby influencing the pathological cascade initiated by α-synuclein. Specifically, hypomethylation of PP2A correlates with increased α-synuclein aggregation and neurotoxicity in vivo, establishing a direct mechanistic link between PP2A post-translational modification and neurodegenerative processes.

To elucidate these relationships, the researchers employed sophisticated mouse models genetically engineered to exhibit varying methylation patterns of PP2A. Through behavioral assays, immunohistochemistry, and biochemical analyses, they documented that mice with reduced PP2A methylation displayed pronounced motor deficits, cognitive impairment, and enhanced α-synucleinopathy, closely mimicking human disease manifestations. These findings underscore the pathological significance of PP2A methylation beyond associative correlations.

The study delves deeply into the molecular dynamics of PP2A methylation regulation, highlighting the roles of leucine carboxyl methyltransferase-1 (LCMT-1) and protein phosphatase methylesterase-1 (PME-1) as the enzymes responsible for opposing methylation states. An imbalance favoring demethylation by PME-1 exacerbates α-synuclein aggregation, suggesting that therapeutic targeting of these modifying enzymes could recalibrate PP2A activity, thus mitigating neurodegeneration.

Importantly, modulating PP2A methylation was shown to influence downstream signaling pathways implicated in neuronal survival and synaptic plasticity. The altered phosphatase activity impacts kinases and substrates involved in oxidative stress response, mitochondrial function, and protein degradation machinery, thereby amplifying neurodegenerative cascades. This interconnected network signifies that restoring PP2A methylation homeostasis could simultaneously counter multiple pathological processes.

The implications of these findings extend to drug development, where small molecules or biologics designed to enhance LCMT-1 activity or inhibit PME-1 could offer disease-modifying potentials. Previous attempts to target α-synuclein aggregation directly have met limited success, but this study proposes a novel therapeutic paradigm based on enzymatic regulation upstream in the pathological pathway, potentially offering improved efficacy and specificity.

Further, the research highlights the importance of epigenetic and post-translational modifications in neurodegeneration, areas that have gained traction but require more rigorous exploration. PP2A methylation represents a crucial node where genetic predispositions and environmental factors intersect, providing a nexus for future studies examining disease pathogenesis and patient stratification.

Methodologically, the study incorporated state-of-the-art proteomics and phosphoproteomics to map the alterations in protein networks contingent on PP2A methylation status. This systems biology approach revealed unexpected interactions and feedback loops, demonstrating the multifaceted nature of PP2A’s role in neuronal health and disease, which may inspire comprehensive biomarker discovery.

The comprehensive behavioral analysis in mouse models further confirmed that PP2A methylation state is not just a molecular curiosity but directly translates into functional deficits akin to those observed in degenerative neurological conditions. This translational aspect is critical for validating the relevance of molecular findings in clinical contexts and for the future design of experimental therapeutics.

Interestingly, the study also detected changes in neuroinflammation concomitant with PP2A methylation alterations, suggesting an interplay between phosphatase activity and immune responses in the brain. Given that neuroinflammation is a known contributor to disease progression in synucleinopathies, this finding enriches the understanding of how metabolic and immune pathways converge to influence neurodegeneration.

In summary, Maddila et al. have provided compelling evidence that the methylation state of PP2A is a pivotal factor in modulating α-synuclein pathology. This epigenetic regulation governs enzymatic activity that either fosters or protects against the toxic accumulation of pathological protein aggregates, offering a promising target for novel therapeutic strategies aimed at halting or reversing disease progression.

As the quest for effective treatments against Parkinson’s and related disorders continues, these insights pave the way for a new class of interventions. Efforts to fine-tune PP2A methylation and restore its physiological functions could redefine the landscape of neurodegenerative disease therapeutics, shifting from symptomatic management toward addressing fundamental molecular causes.

Future investigations will likely explore the detailed mechanisms by which PP2A methylation influences other critical signaling pathways and determine how these findings generalize across different models and potentially to human patients. Understanding interindividual variability and the impact of genetic background on PP2A regulation may also uncover personalized therapeutic opportunities.

In conclusion, this study constitutes a significant advance in neuroscience research, marking a critical step toward deciphering the complex molecular etiology of α-synucleinopathies. By illuminating the impact of PP2A methylation on neurodegeneration, Maddila and colleagues deliver a beacon of hope for those affected by these devastating diseases and chart a promising course for future research and clinical innovation.

Subject of Research: Protein Phosphatase 2A methylation and its effect on α-synucleinopathy in neurodegenerative disease models.

Article Title: Protein phosphatase 2A methylation state impacts α-synucleinopathy in mouse models.

Article References:
Maddila, S., Hassanzadeh, K., Liu, J. et al. Protein phosphatase 2A methylation state impacts α-synucleinopathy in mouse models. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03045-7

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03045-7

Neuronal migration is a critical event during cortical development, underpinning the precise layering of the brain’s cerebral cortex. This ordered radial migration ensures the organized arrangement and connectivity vital for cognitive functions. Until now, the molecular drivers orchestrating this migration have been incompletely understood. The latest findings by Chen, Chen, Qi, and colleagues add JMY to the select cadre of proteins that not only facilitate cytoskeletal remodeling but also regulate gene expression in migrating neurons, positioning it as a key regulatory hub.

JMY, historically studied for its dual roles in actin nucleation and transcription coactivation, emerges in this context as more than a structural scaffold. The study reveals that JMY’s involvement transcends cytoskeletal rearrangements, directly impacting the transcriptional programs that govern neuronal motility. Through a series of elegant in vitro and in vivo experiments, the researchers meticulously traced how JMY modulates actin polymerization at the leading edge of migrating neurons, simultaneously activating pathways that sustain migratory competence over extended periods.

One of the most striking insights is the demonstration that JMY localizes dynamically within migrating neurons, concentrating at sites of active cytoskeletal remodeling. This localization underpins its function as a molecular switch that integrates extracellular cues with intracellular responses, effectively translating environmental signals into coordinated movements. Such spatial regulation offers a nuanced understanding of how migrating neurons negotiate the extracellular matrix and cellular obstacles during their journey to the cortical plate.

Intriguingly, the research team employed advanced imaging techniques including live-cell fluorescence microscopy, enabling real-time visualization of JMY distribution and its coordination with actin filaments. This technological approach provided unprecedented resolution in observing the transient and rapid changes in cytoskeletal architecture fundamental to cell migration. Their findings underscore the synergy between JMY’s actin nucleation capacity and its transcriptional coactivator function, establishing a unified mechanism facilitating neuronal locomotion.

Beyond the cellular and molecular scale, the study delves into the physiological implications of disrupted JMY activity. Utilizing genetic knockdown models in rodents, the researchers demonstrated that diminished JMY expression correlates with significant defects in cortical layering and aberrant neuronal positioning. These phenotypic abnormalities mimic some features observed in neurodevelopmental disorders, suggesting that JMY dysfunction could contribute to pathological states such as epilepsy or intellectual disabilities.

The dual functionality of JMY poses fascinating evolutionary questions about protein versatility in neuronal development. By juggling cytoplasmic and nuclear roles, JMY exemplifies the molecular multitasking that may be critical in the highly orchestrated environment of brain maturation. This multifunctionality could provide a rapid-response system adapting the migratory machinery to varying developmental signals, ensuring fidelity in cortical assembly.

Furthermore, the research highlights the potential for therapeutic targeting of JMY or its downstream pathways. If aberrant neuronal migration underlies certain neurological disorders, correcting or modulating JMY activity might restore normal neuronal positioning and circuit formation. This possibility invites a new line of inquiry into pharmacological or genetic interventions aimed at harnessing JMY’s regulatory capacity.

Importantly, the molecular interactions of JMY extend beyond actin and transcription factors, encompassing signaling cascades pivotal to cellular motility. The study identifies links between JMY and Rho GTPases, master regulators of cytoskeleton dynamics, which reinforce the centrality of JMY in integrating signaling to mechanical execution. This integrative model positions JMY as a node within a complex network coordinating the physical and regulatory requirements of migration.

The discovery also shines a light on the temporal regulation of neuron migration, as JMY expression levels and activity fluctuate during critical windows of cortical development. This temporal patterning provides clues into how neurons synchronize their progress to avoid migratory delays or premature arrest, factors that can severely disrupt cortical organization and function.

Chen et al.’s work sets a new benchmark for the depth of understanding needed to unravel brain development’s complexity. By combining molecular biology, imaging, genetic manipulation, and developmental neurobiology, the study provides a comprehensive picture that bridges gaps between molecular mechanisms and their phenotypic outcomes. This multidisciplinary approach is likely to inspire further research into multifunctional proteins in neural systems.

In summary, the identification of JMY as a promoter of radial migration revitalizes the field with fresh insights into the cellular choreography of cortical development. Its dual role in cytoskeletal modulation and transcriptional regulation makes it a unique and compelling subject for future investigations into brain formation and disorders. As research continues, the implications of manipulating such a protein will reverberate across developmental neuroscience and clinical neurology.

Looking ahead, future studies must dissect the detailed molecular interactions that regulate JMY’s switch between cytoplasmic and nuclear compartments, as well as its crosstalk with other proteins in the migratory machinery. Additionally, exploring variations of JMY function across different neuronal types and brain regions could uncover diverse roles in neurodevelopment and plasticity, further enriching our understanding of the brain’s architectural blueprint.

This seminal discovery not only deepens our grasp of neuronal migration but also catalyzes a broader reevaluation of multifunctional proteins in neurobiology. By revealing how a single protein can seamlessly integrate mechanical and genetic control, the work of Chen and colleagues paves the way for innovative strategies to combat neurodevelopmental disorders and optimize brain repair mechanisms in the future.

Subject of Research: Junction-mediating and regulatory protein (JMY) and its role in radial migration of cortical neurons

Article Title: Junction-mediating and regulatory protein (JMY) is a promoting protein for radial migration of cortical neurons

Article References:
Chen, Xr., Chen, Zy., Qi, Sy. et al. Junction-mediating and regulatory protein (JMY) is a promoting protein for radial migration of cortical neurons. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-02974-7

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-02974-7

The study, titled “Endothelial TDP-43 Depletion Disrupts Core Blood-Brain Barrier Pathways in Neurodegeneration,” was led by Omar Moustafa Fathy, a promising MD/Ph.D. candidate working within the UConn Center for Vascular Biology. This work is particularly significant as it showcases the collaborative efforts of Fathy and his team, who worked under the mentorship of Dr. Patrick A. Murphy, an associate professor and interim director of the Center for Vascular Biology. Importantly, the team collaborated with Dr. Riqiang Yan, a well-respected figure in the field of Alzheimer’s research, enhancing the credibility and depth of the findings.

The research sheds light on a critical yet often overlooked aspect of neurodegenerative diseases—vascular dysfunction. The blood-brain barrier is crucial for maintaining central nervous system homeostasis, yet previous studies have primarily concentrated on neuronal damage, neglecting the role of endothelial cells that form the inner lining of blood vessels. Understanding this relationship is paramount, as endothelial cells contribute significantly to the integrity and functionality of the blood-brain barrier.

To investigate this phenomenon, the research team developed a novel methodology that segregates endothelial cells from frozen tissue samples, innovatively using an NIH-sponsored biobank. They employed inCITE-seq, a sophisticated technique that allows for the precise measurement of protein-level signaling in individual cells. This application marked the first time such a method was utilized in human tissues, yielding unprecedented insights into the signaling pathways associated with endothelial cells in neurodegenerative conditions.

One of the critical findings from the study was the depletion of TDP-43, an RNA-binding protein that has been genetically linked to diseases like ALS and FTD and is commonly disrupted in Alzheimer’s disease. Interestingly, this depletion was observed in endothelial cells from patients suffering from these neurodegenerative diseases, suggesting a shared pathological mechanism across diseases that were previously studied independently. This insight directs attention toward a broader understanding of neurodegeneration as a disease process that encompasses vascular components, not just neuronal ones.

Murphy emphasized the implications of these findings, noting the paradigm shift in our understanding of blood vessels. “It’s easy to think of blood vessels as passive pipelines,” he stated. “However, our findings suggest that they actively participate in shaping the disease progression across various neurodegenerative disorders.” The research indicates that the changes observed in endothelial cells are not merely collateral damage but rather integral components of disease pathology. This recognition opens the door for novel therapeutic interventions targeting vascular health.

The collective effort from UConn’s researchers not only breaks ground in the field of neurobiology but also presents potential pathways for the development of new biomarkers. The identification of specific endothelial cell dysfunctions may help in creating diagnostic tools launched from blood samples of patients afflicted by these debilitating diseases, fostering earlier interventions and personalized treatment strategies.

Throughout the study, funding was a critical facilitator to their success. Resources were provided through startup funds from the UConn School of Medicine, along with competitive grants from the NIH’s National Heart, Lung, and Blood Institute and the American Heart Association. These financial supports underscore the importance of backing interdisciplinary research that seeks to bridge gaps across various fields, emphasizing the interconnectedness of vascular biology and neurodegeneration research.

Future studies will likely continue dissecting the complexities surrounding endothelial cell roles in brain health. As advancements in technology and methodology evolve, researchers aim to further characterize and understand how these cells can respond and adapt in the context of neurodegeneration. Some scholars speculate that uncovering these relationships holds the key to breakthroughs in treating or even preventing such conditions.

Ultimately, the research by Fathy, Murphy, and their collaborators presents a compelling narrative of how interdisciplinary work can pave the way for novel insights into longstanding medical challenges. It illustrates a pivotal moment where the study of vascular biology intersects with neurology, fostering a more comprehensive understanding of the mechanisms that contribute to debilitating diseases. The ability to effectively translate these discoveries into clinical applications could revolutionize how we approach neurodegenerative disease management and treatment in the future.

As this crucial research begins to reverberate throughout the scientific community, it sparks discussions about the potential for designing therapies that target vascular aspects directly involved in neurodegeneration. Moving forward, this could change the future of treatments for these complex diseases by moving beyond the traditional neuronal-centric view and incorporating a more holistic approach that considers the intricate relationships within the brain’s microenvironment.

The ongoing dialogue among researchers, clinicians, and academic institutions highlights the importance of continued collaboration in unlocking the mysteries surrounding neurodegenerative diseases. The pursuit of knowledge in this area is relentless, driven by the urgent need to address the growing incidence of these disorders as populations age. Each new finding builds upon previous victories and setbacks in the quest for more effective treatments, aiming to bring hope to those affected by such devastating illnesses.

In summary, the findings from the UConn research team represent an essential step forward in neurology and vascular biology, unveiling how endothelial dysfunction may play an equally pivotal role in neurodegenerative processes alongside neuronal dysfunction. By fostering this integrated perspective, the potential for novel therapeutic interventions broadens, paving the way for improved health outcomes in individuals affected by these chronic conditions.

Subject of Research: Endothelial cells’ role in neurodegenerative diseases
Article Title: Endothelial TDP-43 depletion disrupts core blood-brain barrier pathways in neurodegeneration
News Publication Date: 14-Mar-2025
Web References: https://urldefense.com/v3/__https:/www.nature.com/articles/s41593-025-01914-5__;!!Cn_UX_p3!lNxCmhXLYp-lykv2BZo0-goVYwrwuYaYX2VK66NFCpGEq_ogSxHomGzLCNtOK74e7t209tyD1xXBlYhYUw%24
References: [Not applicable as per instruction]
Image Credits: UConn Health Photo by Tina Encarnacion

Keywords: Endothelial cells, Neurodegenerative diseases, Alzheimer’s disease, Amyotrophic lateral sclerosis, Blood-brain barrier, Vascular biology, Neurodegeneration, TDP-43, Research collaboration, Biomarkers, Disease mechanisms.